- Justice and Law Enforcement
- Research and Development
- Science and Technology
- Taxation and Finance
Subject Matter Details
Grant, Contribution or Other Financial Benefit
- In terms of research and development, we lobby for support of cystic fibrosis research initiatives that improve the health and wellness of Canadians living with cystic fibrosis.
- In terms of science and technology, we work toward the development of precision and personalized medicines that target the basic defect of cystic fibrosis. We are exploring how the federal government may support these efforts through partnership and funding.
- Increased federal investment in health-related research. We worked with the Health Charities Coalition of Canada (HCCC) to draft content for a press release urging the federal government to invest more in basic science in Canada.
Policies or Program
- Advocating for the use of precision medicine tools in access to medicines decision-making processes.
- Common Drug Review, importance of meaningful public/patient input into the drug review process
- Encouraging the development of a rare disease strategy in Canada (similar to the policies for rare diseases in Europe and the United States).
- Improving access to precision medicines for Canadians with cystic fibrosis and other rare diseases.
- Participating in consultations on national pharmacare
- With respect to Health, we advocate for access to cystic fibrosis (CF) medicines and treatments, the development of a rare disease strategy, and for improved access to disability supports for people with CF. This includes any funding required to support the development and implementation of these policy and legislative proposals. The exact amount of funding has yet to be established and would involve further discussions with government officials.
- With respect to disability, we advocate for recognition of and supports for people with episodic disabilities.
- Health Canada with respect to the regulation of pancreatic enzymes used in the management of cystic fibrosis. Recommend product should be listed on Schedule F to the Food and Drugs Regulations.
- Participated in consultations on regulatory changes to the Patented Medicines Price Review Board (PMPRB) and provided written submissions.
The lobbyist has arranged or expects to arrange one or more meetings on behalf of the client between a public office holder and any other person in the course of this undertaking.
Canada Revenue Agency (CRA)
Canadian Institutes of Health Research (CIHR)
Finance Canada (FIN)
Health Canada (HC)
House of Commons
Patented Medicine Prices Review Board (PMPRB)
Prime Minister's Office (PMO)
Public Health Agency of Canada (PHAC)
Senate of Canada
Statistics Canada (StatCan)
End date of the last completed financial year:
List of Government Funding
Funding Received in Last Financial Year
Funding Expected in Current Financial Year
British Columbia Gaming
British Columbia Ministry of Health
Client Contact Information
2323 Yonge Street
Toronto, ON M4P 2C9
Principal representative of the client
Kelly Grover, President and Chief Executive Officer
Parent Company Information
Cystic Fibrosis Canada / Fibrose kystique Canada is not a subsidiary of any other parent companies.
Coalition Members Information
Cystic Fibrosis Canada / Fibrose kystique Canada is not a coalition.
Person or Organization with a Direct Interest Beneficiary Information
The activities of Cystic Fibrosis Canada / Fibrose kystique Canada are not controlled or directed by another person or organization with a direct interest in the outcome of this undertaking.
Subsidiary Beneficiary Information
Cystic Fibrosis Canada / Fibrose kystique Canada does not have any subsidiaries that could have a direct interest in the outcome of the undertaking
No public offices held
50 O'Connor Street
Ottawa,, ON K1P 6L2
Consultant Firm and Address
Hill+Knowlton Strategies / Hill+Knowlton Stratégies
50 O'Connor Street
Ottawa,, ON K1P 6L2